Y444 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×Ç÷ÀüÁ¦[Ç÷¼ÒÆÇÀÀÁý¾ïÁ¦Á¦] | Antithrombotic drugs [platelet-aggregation inhibitors] causing adverse effects in therapeutic use |
 |
Y445 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç÷Àü¿ëÇØÁ¦ | Thrombolitic drugs causing adverse effects in therapeutic use |
 |
Y446 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â õ¿¬ Ç÷¾× ¹× Ç÷¾× »ý»ê¹° | Natural blood and blood products causing adverse effects in therapeutic use |
 |
Y447 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç÷Àå´ëÄ¡¹° | Plasma substitutes causing adverse effects in therapeutic use |
 |
Y449 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ Ç÷¾×¼ººÐ¿¡ ÀÛ¿ëÇÏ´Â ¾àÁ¦ | Other and unspecified agent affecting blood constituents causing adverse effects in therapeutic use |
 |
Y45 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÁøÅëÁ¦, ÇØ¿Á¦ ¹× Ç׿°ÁõÁ¦ | Analgesics, antipyretics and anti-inflammatory drugs causing adverse effects in therapeutic use |
 |
Y450 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾ÆÆí ¹× °ü·Ã ÁøÅëÁ¦ | Opioids and related analgesics causing adverse effects in therapeutic use |
 |
Y451 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ì¸®½Ç·¹ÀÌÆ® | Salicylates causing adverse effects in therapeutic use |
 |
Y452 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÇÁ·ÎÇǿ»êÀ¯µµÃ¼ | Propionic acid derivatives causing adverse effects in therapeutic use |
 |
Y452 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÇÁ·ÎÆÄ³ë»êÀ¯µµÃ¼ | Propanoic acid derivatives causing adverse effects in therapeutic use |
 |
Y453 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ºñ½ºÅ×·ÎÀ̵åÇ׿°ÁõÁ¦ | Other nonsteroidal anti-inflammatory drugs [NSAID] causing adverse effects in therapeutic use |
 |
Y454 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×·ù¸¶Æ¼½ºÁ¦ | Antirheumatics causing adverse effects in therapeutic use |
 |
Y455 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â 4-¾Æ¹Ì³ëÆä³îÀ¯µµÃ¼ | 4-Aminophenol derivatives causing adverse effects in therapeutic use |
 |
Y458 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ÁøÅëÁ¦ ¹× ÇØ¿Á¦ | Other analgesics and antipyretics causing adverse effects in therapeutic use |
 |
Y459 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ ÁøÅëÁ¦, ÇØ¿Á¦ ¹× Ç׿°ÁõÁ¦ | Analgesics, antipyretics and anti-inflammatory drug, unspecified causing adverse effects in therapeutic use |
 |
Y46 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×°£ÁúÁ¦ ¹× ÇׯÄŲ½¼Á¦ | Antiepileptics and antiparkinsonism drugs causing adverse effects in therapeutic use |
 |
Y460 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¼®½Ã´Ï¸¶À̵å | Succinimides causing adverse effects in therapeutic use |
 |
Y461 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¿Á»çÁ¹¸®µð³×µð¿Â | Oxazolidinediones causing adverse effects in therapeutic use |
 |
Y462 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â È÷´ÜÅäÀÎÀ¯µµÃ¼ | Hydantoin derivative causing adverse effects in therapeutic use |
 |
Y463 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â µ¥¿Á½Ã¹ÙºñÃò·¹ÀÌÆ® | Deoxybarbiturate causing adverse effects in therapeutic use |
 |